Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Investigational New Drugs is Scopus-indexed (Q2, CiteScore 5.8), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer.
Checked against the index lists dated .
ISSN 0167-6997Verify ISSN ↗1573-0646Verify ISSN ↗
Publisher: Springer
Cost to publish: About US$4,690 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 71 / 278 | 74th | Q2 |
| Oncology | 121 / 428 | 71st | Q2 |
| Pharmacology | 111 / 328 | 66th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1983–present, best quartile Q2, CiteScore 5.8.
Investigational New Drugs is Q2 in Pharmacology (medical) (rank 71 of 278), Q2 in Oncology (rank 121 of 428) and Q2 in Pharmacology (rank 111 of 328), by CiteScore 2025.
Investigational New Drugs is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.8, which places it in quartile Q2 at the 74th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.816, quartile Q2, with an H-index of 104.
The publisher lists an article processing charge of about US$4,690 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Investigational New Drugs is published by Springer. Its print ISSN is 0167-6997 and its online ISSN is 1573-0646.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Investigational New Drugs has an h-index of 116 and a 2-year mean of 4.06 citations per paper (OpenAlex). Its Scopus CiteScore is 5.8, quartile Q2. On 2-year citations it ranks #49 of 271 Scopus journals in Pharmacology (medical).
Investigational New Drugs published 101 papers in 2025; its busiest recent year was 2019 with 177. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2025–2026), authors are most often from China (34.2%), United States (11.6%) and Japan (10.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 5 retracted papers are recorded (1.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.